LQDA (Liquidia) Long-Term Debt: $127.6 Mil (As of Mar. 2026)


LQDA Liquidia Corp LQDA
67 GF Score
Price $81.45
GF Value $229.09
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Liquidia Long-Term Debt?

Liquidia LQDA +2.49% 67 Long-Term Debt is $127.6 Mil as of Mar. 2026. GuruFocus rates LQDA with a GF Score™ of 67/100 and a GF Value™ of $229.09 (Possible Value Trap). The stock has 6 warning signs investors should review.

Liquidia's Long-Term Debt for the quarter that ended in Mar. 2026 was $127.6 Mil.

Liquidia's quarterly Long-Term Debt declined from Sep. 2025 ($136.4 Mil) to Dec. 2025 ($132.9 Mil) and declined from Dec. 2025 ($132.9 Mil) to Mar. 2026 ($127.6 Mil).

Liquidia's annual Long-Term Debt increased from Dec. 2023 ($43.4 Mil) to Dec. 2024 ($95.3 Mil) and increased from Dec. 2024 ($95.3 Mil) to Dec. 2025 ($132.9 Mil).

Liquidia  (NAS:LQDA) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Liquidia Long-Term Debt Related Terms

Liquidia Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Liquidia's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Liquidia Long-Term Debt Chart

Liquidia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.41 19.88 43.42 95.27 132.94

Liquidia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 103.18 149.47 136.45 132.94 127.64
LQDA
67GF Score
Liquidia Corp LQDA
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $127.6 Mil mean?
Liquidia (LQDA) has a Long-Term Debt of $127.6 Mil as of Mar. 2026.
Is Liquidia's Long-Term Debt too high?
Liquidia's current Long-Term Debt is $127.6 Mil. Overall, Liquidia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Liquidia's Long-Term Debt compare to LNTH and HIMS?
Liquidia's Long-Term Debt of $127.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Liquidia's current Long-Term Debt is $127.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liquidia stock overvalued right now?
Based on GuruFocus' analysis, Liquidia (LQDA) is currently considered Possible Value Trap. The stock's GF Value™ is $229.09, compared to a current price of $81.45 — trading 64.4% below its estimated fair value. The current Long-Term Debt is $127.6 Mil. Liquidia's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Liquidia (LQDA), the current Long-Term Debt is $127.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Liquidia (LQDA) Overvalued in 2026?

Based on GuruFocus' analysis, Liquidia stock appears to be undervalued. The current stock price of $81.45 is trading 64.4% below its estimated GF Value™ of $229.09. GuruFocus considers Liquidia to be Possible Value Trap.

Key valuation signals for LQDA:

  • Long-Term Debt: $127.6 Mil
  • GF Value™: $229.09 vs. price of $81.45 (64.4% below fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the LQDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Liquidia Business Description

Other Exchanges LT4:Germany
Address 419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
67GF Score

Get the complete analysis for LQDA

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$81.45
Price
$229.09
GF Value